|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
JP2020517699A
(ja)
|
2017-04-26 |
2020-06-18 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
ジスルフィド結合の還元を最小限にする抗体製造法
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
SG11201909941QA
(en)
*
|
2017-05-02 |
2019-11-28 |
Merck Sharp & Dohme |
Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
|
CN110913906A
(zh)
|
2017-05-02 |
2020-03-24 |
默沙东公司 |
抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
|
|
JP7348072B2
(ja)
|
2017-06-01 |
2023-09-20 |
コンピュジェン リミテッド |
三重併用抗体療法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
CN111201024A
(zh)
*
|
2017-08-07 |
2020-05-26 |
菲奥医药公司 |
经化学修饰的寡核苷酸
|
|
WO2019037052A1
(zh)
*
|
2017-08-24 |
2019-02-28 |
深圳市博奥康生物科技有限公司 |
靶向沉默wucam的shrna
|
|
CN108558997B
(zh)
*
|
2017-10-20 |
2021-10-08 |
中国人民解放军第四军医大学 |
一种重组融合蛋白TIGIT-Fc及其抗移植排斥反应的应用
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
MX428543B
(es)
*
|
2018-02-28 |
2025-11-13 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
WO2019178356A1
(en)
*
|
2018-03-14 |
2019-09-19 |
Dana-Farber Cancer Institute, Inc. |
Engineered cells, t cell immune modulating antibodies and methods for using the same
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EP3841123A2
(en)
|
2018-08-23 |
2021-06-30 |
Seagen Inc. |
Anti-tigit antibodies
|
|
KR102084196B1
(ko)
*
|
2018-08-29 |
2020-03-03 |
연세대학교 산학협력단 |
면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
|
|
MX2021004356A
(es)
|
2018-10-18 |
2021-05-31 |
Merck Sharp & Dohme Llc |
Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
|
|
MA54089A
(fr)
|
2018-10-31 |
2022-02-09 |
Merck Sharp & Dohme |
Anticorps anti-pd-1 humain et procédés d'utilisation associés
|
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
EP4003399A4
(en)
|
2019-07-26 |
2023-04-26 |
Board Of Trustees Of Michigan State University |
METHODS OF PREVENTING OR TREATMENT OF FATTY ACID DEGENERATION OF SKELETON MUSCLES
|
|
KR20220082007A
(ko)
|
2019-10-08 |
2022-06-16 |
넥틴 테라퓨틱스 리미티드 |
폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
|
|
US20230340122A1
(en)
*
|
2019-11-05 |
2023-10-26 |
Glaxosmithkline Intellectual Property (No. 4) Ltd. |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
WO2021113831A1
(en)
|
2019-12-05 |
2021-06-10 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
|
US20230037966A1
(en)
*
|
2020-01-07 |
2023-02-09 |
The Trustees Of The University Of Pennsylvania |
Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
|
|
CN115916247B
(zh)
*
|
2020-04-19 |
2025-04-01 |
奥美药业有限公司 |
人tigit特异性单域抗体及其应用
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
WO2021257124A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
CN111763660A
(zh)
*
|
2020-08-07 |
2020-10-13 |
南京大学 |
一种重组溶瘤痘苗病毒及其制备方法和应用
|
|
EP4277904A1
(en)
|
2021-01-15 |
2023-11-22 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
MX2023009113A
(es)
|
2021-02-03 |
2023-08-10 |
Seagen Inc |
Conjugados y compuestos inmunoestimulantes.
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
CN113030487B
(zh)
*
|
2021-03-31 |
2023-11-10 |
山东大学齐鲁医院 |
Cd155在宫颈癌诊治中的应用
|
|
CA3217279A1
(en)
|
2021-05-04 |
2022-11-10 |
Olga Ignatovich |
Anti-tigit antibodies and methods of use thereof
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
CN118871463A
(zh)
|
2021-07-28 |
2024-10-29 |
基因泰克公司 |
用于治疗癌症的方法和组合物
|
|
KR20240046905A
(ko)
*
|
2021-08-20 |
2024-04-11 |
아케소 바이오파마, 인크. |
항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
KR102680316B1
(ko)
*
|
2021-11-01 |
2024-07-01 |
오토텔릭바이오 주식회사 |
안티센스 올리고뉴클레오타이드
|
|
CA3259975A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CN115043910B
(zh)
*
|
2022-03-25 |
2023-04-07 |
湖南中晟全肽生化有限公司 |
抑制tigit与cd155结合的多肽及其应用
|
|
EP4518905A1
(en)
|
2022-05-06 |
2025-03-12 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
JP2025523387A
(ja)
|
2022-06-07 |
2025-07-23 |
ジェネンテック， インコーポレイテッド |
抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法
|
|
IL318450A
(en)
|
2022-08-03 |
2025-03-01 |
Seagen Inc |
Immunostimulatory ANTI-PD-L1-Drug conjugates
|
|
EP4321522A1
(en)
|
2022-08-12 |
2024-02-14 |
Seagen Inc. |
Cytotoxic compounds and conjugates thereof
|
|
CN116284395B
(zh)
*
|
2022-12-12 |
2024-11-08 |
合肥天港免疫药物有限公司 |
抗cd155的抗体及其应用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|